Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation

被引：0
|
作者：
Perrottet, Nancy [1 ]
Manuel, Oriol [4 ]
Venetz, Jean-Pierre [2 ]
Lamoth, Frederic [2 ]
Decosterd, Laurent A. [1 ]
Buclin, Thierry [1 ]
Biollaz, Jerome [1 ]
Meylan, Pascal [3 ]
Pascual, Manuel [2 ]
机构：
[1] Univ Hosp CHUV, Clin Pharmacol & Toxicol, Lausanne, Switzerland
[2] Univ Hosp CHUV, Organ Transplant Ctr, Lausanne, Switzerland
[3] Univ Hosp CHUV, Inst Microbiol, Lausanne, Switzerland
[4] Univ Alberta, Edmonton, AB, Canada
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2008年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [41] Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients
    Lee, J. H.
    Hwang, S. D.
    Song, J. H.
    Kim, J. H.
    Kim, H. Y.
    Lee, D. Y.
    Oh, J. S.
    Sin, Y. H.
    Kim, J. K.
    [J]. TRANSPLANTATION PROCEEDINGS, 2018, 50 (08) : 2485 - 2488
  • [42] Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation
    Bachier, C
    Shaughnessy, P
    Wall, D
    Grimley, M
    Carrum, G
    Freytes, C
    Callander, N
    Walsh, T
    LeMaistre, CF
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 90 - 91
  • [43] Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection
    Veceric-Haler, Zeljka
    Bizjak, Bostjan
    Romozi, Karmen
    Arnol, Miha
    [J]. CLINICAL NEPHROLOGY, 2017, 88 : S126 - S130
  • [44] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
  • [45] EXTENDING VALGANCICLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS IS ASSOCIATED WITH LOWER INCIDENCE OF CYTOMEGALOVIRUS INFECTION
    Bizjak, Bostjan
    Veceric-Haler, Zeljka
    Romozi, Karmen
    Arnol, Miha
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 407 - 407
  • [46] SHORT VERSUS EXTENDED TERM VALGANCICLOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IN PEDIATRIC KIDNEY TRANSPLANT
    Hashim, Faris
    Dharnidharka, Vikas
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (04) : A45 - A45
  • [47] Low-Dose Dopamine in Kidney Transplantation
    Ciapetti, M.
    di Valvasone, S.
    di Filippo, A.
    Cecchi, A.
    Bonizzoli, M.
    Peris, A.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4165 - 4168
  • [48] Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant
    Roberts, Matthew B.
    Kotton, Camille N.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (18): : 1802 - 1803
  • [49] Efficacy and safety of low-dose valganciclovir prophylaxis among renal transplant recipients
    Sayilar, Emel Isiktas
    Ergun, Ihsan
    [J]. CUKUROVA MEDICAL JOURNAL, 2020, 45 (01): : 347 - 351
  • [50] What Is the Impact of Late-Onset Cytomegalovirus Disease After Valganciclovir Prophylaxis in Kidney Transplantation?
    Lamoth, Frederic
    Manuel, Oriol
    Venetz, Jean-Pierre
    Faouzi, Mohamed
    Meylan, Pascal
    Pascual, Manuel
    [J]. TRANSPLANTATION, 2008, 86 (09) : 1323 - 1324
12345